Total Payments
$13,426
2024 Payments
$139.34
Companies
7
Transactions
40
Medicare Patients
679
Medicare Billing
$93,712
Payment Breakdown by Category
Other$7,680 (57.2%)
Research$4,255 (31.7%)
Food & Beverage$868.47 (6.5%)
Travel$328.76 (2.4%)
Education$293.60 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,680 | 4 | 57.2% |
| Unspecified | $4,255 | 5 | 31.7% |
| Food and Beverage | $868.47 | 24 | 6.5% |
| Travel and Lodging | $328.76 | 2 | 2.4% |
| Education | $293.60 | 5 | 2.2% |
Payments by Type
General
$9,171
35 transactions
Research
$4,255
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $6,921 | 17 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $5,837 | 10 | $0 (2018) |
| United Therapeutics Corporation | $249.35 | 5 | $0 (2024) |
| ABIOMED | $135.96 | 1 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $132.70 | 2 | $0 (2020) |
| Merck Sharp & Dohme LLC | $75.12 | 4 | $0 (2024) |
| Sandoz Inc. | $74.13 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $139.34 | 5 | Actelion Pharmaceuticals US, Inc. ($74.53) |
| 2023 | $469.31 | 9 | United Therapeutics Corporation ($201.71) |
| 2022 | $18.33 | 1 | United Therapeutics Corporation ($18.33) |
| 2020 | $169.66 | 2 | ABIOMED ($135.96) |
| 2019 | $18.19 | 1 | Actelion Pharmaceuticals US, Inc. ($18.19) |
| 2018 | $4,503 | 5 | Actelion Pharmaceuticals US, Inc. ($2,352) |
| 2017 | $8,108 | 17 | Actelion Pharmaceuticals US, Inc. ($4,323) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $54.99 | General |
| Category: Cardiology | ||||||
| 10/22/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/30/2024 | United Therapeutics Corporation | ORENITRAM (Drug), REMODULIN | Food and Beverage | In-kind items and services | $29.31 | General |
| Category: Pulmonary Arterial Hypertension | ||||||
| 06/21/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/26/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: Cardiology | ||||||
| 12/05/2023 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $99.99 | General |
| Category: Cardiology | ||||||
| 11/01/2023 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $102.47 | General |
| Category: PAH | ||||||
| 09/01/2023 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $9.01 | General |
| Category: Cardiology | ||||||
| 08/23/2023 | United Therapeutics Corporation | TYVASO (Drug), REMODULIN, ORENITRAM | Food and Beverage | In-kind items and services | $94.29 | General |
| Category: PAH | ||||||
| 07/20/2023 | United Therapeutics Corporation | REMODULIN (Drug), ORENITRAM, TYVASO | Food and Beverage | In-kind items and services | $4.95 | General |
| Category: PAH | ||||||
| 05/22/2023 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $44.85 | General |
| Category: Cardiology | ||||||
| 05/21/2023 | Sandoz Inc. | TREPROSTINIL (Drug) | Food and Beverage | In-kind items and services | $74.13 | General |
| Category: PULMONARY ARTERIAL HYPERTENSION | ||||||
| 04/12/2023 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $19.81 | General |
| 04/12/2023 | Merck Sharp & Dohme LLC | — | Education | In-kind items and services | $19.81 | General |
| 06/28/2022 | United Therapeutics Corporation | REMODULIN (Drug) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: PAH | ||||||
| 06/16/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $33.70 | General |
| Category: RESPIRATORY | ||||||
| 01/22/2020 | ABIOMED | Impella (Device) | Food and Beverage | In-kind items and services | $135.96 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/18/2019 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: Cardiology | ||||||
| 11/28/2018 | Actelion Pharmaceuticals US, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| 11/28/2018 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $101.65 | General |
| 10/01/2018 | Bayer HealthCare Pharmaceuticals Inc. | Adempas (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,040.00 | General |
| Category: Cardio-pulmonary | ||||||
| 09/26/2018 | Bayer HealthCare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $12.59 | General |
| Category: Cardio-pulmonary | ||||||
| 04/25/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Education | In-kind items and services | $99.00 | General |
| 12/07/2017 | Actelion Pharmaceuticals US, Inc. | OPSUMIT MACITENTAN (Drug), VELETRI EPOPROSTENOL, TRACLEER BOSENTAN | — | Cash or cash equivalent | $1,475.00 | Research |
| Study: QUERI EXTENSION - AC-052428 USA • Category: CARDIOVASCULAR DISORDERS | ||||||
| 09/27/2017 | Actelion Pharmaceuticals US, Inc. | OPSUMIT MACITENTAN (Drug), VELETRI EPOPROSTENOL, TRACLEER BOSENTAN | — | Cash or cash equivalent | $785.00 | Research |
| Study: QUERI EXTENSION - AC-052428 USA • Category: CARDIOVASCULAR DISORDERS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| QUERI EXTENSION - AC-052428 USA | Actelion Pharmaceuticals US, Inc. | $4,255 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 83 | 133 | $30,557 | $11,991 |
| 2022 | 2 | 99 | 151 | $29,789 | $14,465 |
| 2021 | 5 | 175 | 257 | $60,325 | $27,382 |
| 2020 | 11 | 322 | 457 | $99,600 | $39,874 |
Total Patients
679
Total Services
998
Medicare Billing
$93,712
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 47 | 78 | $20,664 | $8,120 | 39.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 36 | 55 | $9,893 | $3,871 | 39.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 52 | 88 | $19,712 | $9,795 | 49.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 63 | $10,077 | $4,670 | 46.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 48 | 78 | $17,472 | $9,149 | 52.4% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 27 | 47 | $21,103 | $8,337 | 39.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 58 | 80 | $12,720 | $6,334 | 49.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 22 | $4,620 | $1,828 | 39.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 23 | 30 | $4,410 | $1,734 | 39.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 50 | 88 | $39,512 | $15,915 | 40.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 39 | 64 | $14,336 | $5,804 | 40.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 56 | 87 | $13,833 | $5,438 | 39.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 45 | 61 | $12,810 | $5,188 | 40.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 42 | 67 | $9,849 | $3,952 | 40.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 11 | 11 | $3,740 | $1,452 | 38.8% |
| 99292 | Critical care delivery critically ill or injured patient | Facility | 2020 | 11 | 11 | $2,486 | $1,001 | 40.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 18 | 18 | $1,854 | $666.60 | 36.0% |
| 94726 | Determination of lung volumes using plethysmography | Facility | 2020 | 18 | 18 | $468.00 | $179.62 | 38.4% |
| 94729 | Measurement of lung diffusing capacity | Facility | 2020 | 19 | 19 | $361.00 | $140.87 | 39.0% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Facility | 2020 | 13 | 13 | $351.00 | $135.76 | 38.7% |
About Dr. Michael Eggert, MD
Dr. Michael Eggert, MD is a Pulmonary Disease healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790750099.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Eggert, MD has received a total of $13,426 in payments from pharmaceutical and medical device companies, with $139.34 received in 2024. These payments were reported across 40 transactions from 7 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($7,680).
As a Medicare-enrolled provider, Eggert has provided services to 679 Medicare beneficiaries, totaling 998 services with total Medicare billing of $93,712. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location Norfolk, VA
- Active Since 02/21/2006
- Last Updated 02/25/2025
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1790750099
Products in Payments
- Adempas (Drug) $5,837
- OPSUMIT MACITENTAN (Drug) $4,308
- TYVASO (Drug) $196.76
- OPSUMIT (Drug) $183.53
- Impella (Device) $135.96
- UPTRAVI (Drug) $78.54
- TREPROSTINIL (Drug) $74.13
- WINREVAIR (Biological) $35.50
- OFEV (Drug) $33.70
- ORENITRAM (Drug) $29.31
- REMODULIN (Drug) $23.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Norfolk
Dr. Zachary Young, Md, MD
Pulmonary Disease — Payments: $8,340
Pulmonary Disease $8,340
Sherif El Mahdy, Md, MD
Pulmonary Disease — Payments: $6,791
Pulmonary Disease $6,791
Manuela Delacruz, M.d, M.D
Pulmonary Disease — Payments: $2,391
Pulmonary Disease $2,391
Xian Qiao, Md, MD
Pulmonary Disease — Payments: $605.84
Pulmonary Disease $605.84
Timothy Fusiak, Do, DO
Pulmonary Disease — Payments: $561.30
Pulmonary Disease $561.30
Michael Hooper, Md, MD
Pulmonary Disease — Payments: $299.13
Pulmonary Disease $299.13